Has MYLAN PHARMACEUTICALS INC had other FDA enforcement actions?

Yes. Argus HQ has recorded 4 total FDA actions tied to MYLAN PHARMACEUTICALS INC: 0 warning letters, 4 recalls, 0 approval records, and 0 Form 483 inspection citations.

What kind of FDA record is this?

This is an Argus HQ record of a FDA Recall, tagged high severity by Argus HQ. FDA published the underlying record on 2026-08-26; Argus observed and indexed it on 2026-09-08.

Where can I verify this record directly with FDA?

The verbatim FDA source record is the source of truth — Argus HQ links directly to it below. Always confirm against fda.gov before acting.

.hq

fda_recall · drug_recall · high

Mylan Pharmaceuticals Inc — Class II recall: Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx on…

Name: FDA Recall Record — MYLAN PHARMACEUTICALS INC
Creator: Argus HQ
Published: 2026-08-26
License: https://argushq.ai/methodology

Event date: 2026-08-26 00:00:00Z
Observed: 2026-09-08 04:20:22Z
Source ID: D-0774-2026
Payload hash: 393fd900eac2beae30253ef8…

Summary

Failed Dissolution Specifications Status: Ongoing.

Entities

MYLAN PHARMACEUTICALS INC

View source record ↗

Frequently asked questions

Has MYLAN PHARMACEUTICALS INC had other FDA enforcement actions?: Yes. Argus HQ has recorded 4 total FDA actions tied to MYLAN PHARMACEUTICALS INC: 0 warning letters, 4 recalls, 0 approval records, and 0 Form 483 inspection citations.
What kind of FDA record is this?: This is an Argus HQ record of a FDA Recall, tagged high severity by Argus HQ. FDA published the underlying record on 2026-08-26; Argus observed and indexed it on 2026-09-08.
Where can I verify this record directly with FDA?: The verbatim FDA source record is the source of truth — Argus HQ links directly to it below. Always confirm against fda.gov before acting.

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). Mylan Pharmaceuticals Inc — Class II recall: Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx on…. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/events/fda-recall-mylan-pharmaceuticals-inc-d-0774-2026

MLA

"Mylan Pharmaceuticals Inc — Class II recall: Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx on…." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/events/fda-recall-mylan-pharmaceuticals-inc-d-0774-2026.

Chicago

Argus HQ Research. "Mylan Pharmaceuticals Inc — Class II recall: Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx on…." Digital Empire Holdings LLC. Accessed September 23, 2026. https://argushq.ai/events/fda-recall-mylan-pharmaceuticals-inc-d-0774-2026.

BibTeX

@misc{argushq_argushq_ai_events_fda_recall_mylan_pharmaceuticals_inc_d_0774_2026_2026,
  title = {Mylan Pharmaceuticals Inc — Class II recall: Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx on…},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/events/fda-recall-mylan-pharmaceuticals-inc-d-0774-2026},
  note = {Accessed: September 23, 2026}
}

Informational only. Not legal, financial, or medical advice.